BioMarin Pharmaceutical Inc. 8-K Summary: Acquisition of Amicus Therapeutics
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 19, 2025, announces that BioMarin Pharmaceutical Inc. (BioMarin) has entered into a definitive Agreement and Plan of Merger to acquire Amicus Therapeutics, Inc. (Amicus). The transaction involves the merger of a BioMarin subsidiary with Amicus, resulting in Amicus becoming a wholly-owned subsidiary of BioMarin.
Key Financial Metrics and Transaction Terms
- Merger Consideration: Amicus shareholders will receive $14.50 per share in cash.
- Equity Awards: Outstanding Amicus options, RSUs, and PSUs will be converted to cash payments based on the $14.50 merger price (for in-the-money options and all RSUs/PSUs).
- Financing: BioMarin has secured a debt financing commitment from Morgan Stanley Senior Funding, Inc. for a $3.65 billion 364-day senior secured bridge loan facility.
- Termination Fee: Amicus is obligated to pay BioMarin a termination fee of $175 million under specific circumstances, including accepting a superior offer or failing to obtain stockholder approval.
- Projected Closing: The parties expect the transaction to close in the second quarter of 2026.
Material Changes and Strategic Outlook
The filing does not report historical financial changes for BioMarin or Amicus for a specific period but outlines significant strategic shifts:
- Portfolio Expansion: The acquisition is intended to diversify BioMarin's rare disease portfolio, specifically adding Amicus's products Galafold, Pombiliti, and Opfolda, as well as the investigational candidate DMX-200 for focal segmental glomerulosclerosis (FSGS).
- Financial Impact: Management expects the deal to be accretive to Non-GAAP Diluted EPS within the first 12 months post-close and substantially accretive beginning in 2027.
- Leverage Targets: BioMarin commits to deleveraging, with an expectation to reach gross leverage of less than 2.5x within two years after closing.
- Patent Exclusivity: The filing notes expectations that U.S. exclusivity for Galafold will extend through January 2037 following the settlement of related patent litigation.
Risks, Contingencies, and Unusual Items
Consummation of the merger is subject to several material conditions and risks:
- Regulatory Approvals: Closing is contingent on the expiration of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act and obtaining necessary approvals from other antitrust and foreign direct investment authorities.
- Stockholder Approval: The transaction requires adoption by holders of a majority of Amicus's outstanding common stock.
- Financing Conditions: The bridge loan commitment is subject to customary conditions and the entry into definitive documentation.
- Forward-Looking Uncertainties: Risks include the inability to realize anticipated synergies, integration challenges, potential disruption to operations, and the possibility that the transaction may not close in the anticipated timeframe or at all.
Key Facts for Investor Verification
- Verify the final terms of the $3.65 billion bridge loan and whether BioMarin intends to replace it with permanent capital markets financing.
- Monitor the status of antitrust reviews and the timeline for the Amicus stockholder vote.
- Review the Merger Agreement (Exhibit 2.1) for specific representations, warranties, and the definition of "Material Adverse Effect."
- Assess the impact of the $175 million termination fee on BioMarin's balance sheet if the deal fails due to a superior offer.
- Confirm the timeline for the deleveraging strategy to achieve <2.5x gross leverage within two years of closing.